Roche pays up to $535mm for epigenetics-focused Tensha Therapeutics
Roche acquired private epigenetics-focused Tensha Therapeutics Inc. for $115mm up front and up to $420mm tied to clinical and regulatory milestones.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.